Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 31, 2022Blood AdvancesOpen Access

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CTCatherine ThiéblemontUniversité Claude Bernard Lyon 1LCLoïc ChartierInstitut National Polytechnique de ToulouseUDUlrich DührsenEssen University Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thiéblemont et al. (2022) studied this question.

synapsesocial.com/papers/6a014eec413f0c047f2d8aa9https://doi.org/10.1182/bloodadvances.2021006923
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era2013 · 967 citations
  2. 2Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity2014 · 569 citations
  3. 3Report on the First International Workshop on interim-PET scan in lymphoma2009 · 761 citations
  4. 4High total metabolic tumor volume at baseline predicts survival independent of response to therapy2020 · 188 citations
  5. 5Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma2016 · 189 citations